Navigation Links
Immtech to Reorganize Research and Development Operations
Date:4/21/2009

NEW YORK, April 21 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Amex: IMM) announced today that the Company is reorganizing its R&D operations. This restructuring will direct resources to business opportunities based on the Company's ongoing discovery program and library of proprietary compounds. With this change, the Company also announced that the position of Senior Vice President for Pharmaceutical Development & Chief Medical Officer is being eliminated. This position was held by Carol Ann Olson, M.D., Ph.D. She will continue to work with Immtech in a consulting role for pharmaceutical development.

"We thank Dr. Olson for her dedication and efforts and wish her well in her future endeavors. Immtech is in discussions with potential joint venture partners regarding co-development of Immtech's proprietary compounds. The Company's organizational structure will continue to evolve so that we can be best positioned to succeed in this dynamic environment." said Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer.

In March 2009, Immtech announced an investment in Gold Avenue Ltd., a privately-held Hong Kong company with interests in tin production in China. The Company recently signed a memorandum of understanding to explore development of strategic business alliances with Beijing Pharmaceutical Group, and it has also obtained various letters of interest from pharmaceutical companies pertaining to the Company's HCV program.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. and subsidiaries (a development stage enterprise) is focused on global development in the healthcare sector and opportunities in China. Immtech aims to apply its established expertise and assets in both new drug development and enhanced healthcare-related services, including research and content distribution for developed and developing countries. For additional information, please visit the Company's website at http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2008 filed on June 18, 2008, and in its other SEC filings and include, but are not limited to: (i) conditions in the credit markets and the general economy; (ii) Immtech's ability to obtain additional funds; (iii) Immtech's ability to manage its remaining resources; (iv) Immtech's ability to continue as a going concern; (v) Immtech's ability to retain key personnel; (vi) the ability of Immtech's scientists and collaborators to discover new compounds; (vii) the availability of additional research grants; (viii) Immtech's ability to obtain regulatory approval of its drug candidates; (ix) the success of Immtech's clinical trials; (x) dependence upon and contractual relationship with partners; (xi) Immtech's ability to protect its intellectual property; and (xii) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Receives Listing Determination Letter
2. Immtech To Reschedule Quarterly Conference Call
3. Immtech Reports Fiscal Third Quarter 2009 Results
4. Immtech Announces Sale of Property Subsidiary in China
5. Immtech Receives Listing Notice From NYSE Alternext US
6. Immtech Reports Fiscal Second Quarter 2009 Results
7. Immtech Investor Conference Call Scheduled for June 25, 2008
8. Immtech Reports Fiscal Year End 2008 Results
9. Immtech Announces Results From Hepatitis C Discovery Program
10. Immtech Announces Update on Business Operations
11. Immtech Investor Conference Call Scheduled for February 22, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... of Platelet Rich Plasma (PRP). PRP systems are used by physicians in areas ... and provide a faster and more efficient healing process. There are many systems ...
(Date:2/22/2017)... ... 22, 2017 , ... Forty-five percent of American respondents feel ... members or friends have also commented about their poor hearing. However, only 13 ... One reason, suggested by 89 percent of American respondents, is that they don’t ...
(Date:2/22/2017)... Isle, North Carolina (PRWEB) , ... February 22, 2017 , ... ... 59% of cats and 54% of dogs, according to the Association for Pet Obesity ... professionals disagreed on key pet food issues such as the benefits of corn and ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, will ... on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar Convention ... our community. We are thrilled to participate in this event because we believe it ...
(Date:2/22/2017)... ... February 22, 2017 , ... Alto-Shaam is pleased to announce ... Oven offers up to four ovens in one. Control temperature, fan speed and ... evenness in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce this game-changing ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017  Soligenix, Inc. (Nasdaq: ... biopharmaceutical company focused on developing and commercializing products ... unmet medical need, announced today that its proprietary ... European patent for the treatment of psoriasis. The ... treatment of skin conditions, complements the method of ...
(Date:2/21/2017)... NEW YORK , Feb. 21, 2017 ... at a CAGR of 6.0% from 2016 to 2021, ... 8.12 billion in 2016. Increasing prevalence of chronic diseases ... infusion pumps to reduce hospital expenditure, steady increase in ... in pain management are some of the key factors ...
(Date:2/21/2017)... YORK , Feb. 21, 2017 Diabetic Shoes ... ... Diabetes can be described as a disease, which is marked ... insulin production and insulin action. The disease has become a ... premature death. Diabetes affects several organs of the body including ...
Breaking Medicine Technology: